Just a few years ago, the weight loss industry revolved around dietary supplements, protein shakes, and fat-burning pills. However, with the emergence of injectable drugs like Wegovy (semaglutide) and Mounjaro (tirzepatide), the market has shifted dramatically. These new medications promise not just to support metabolism but to actually reduce weight by influencing hormonal balance.
In this article, we’ll explore how these drugs work, whether they can replace the nutra segment, and which markets still trust traditional nutraceuticals more.
How do Wegovy and Mounjaro Work?
Both drugs belong to the GLP-1 agonist class, substances that impact insulin levels, appetite, and metabolism:
- Wegovy (semaglutide) – suppresses appetite, slows gastric emptying, and helps reduce calorie intake.
- Mounjaro (tirzepatide) – affects two hormones (GLP-1 and GIP), accelerating fat burning and reducing hunger.
Effectiveness:
According to the STEP study (Semaglutide Treatment Effect in People with Obesity), people taking Wegovy lost an average of 15% of their body weight over 68 weeks.
Mounjaro showed even more impressive results—up to 22.5% weight loss in 72 weeks (SURMOUNT-1 study).
Comparison with nutra products:
For comparison, most traditional weight loss supplements (L-carnitine, green tea extract, CLA) lead to a 2–5% weight reduction over six months. The difference is 3 to 5 times greater!
Where do people trust nutra products more, and where do they prefer injections?
The trend of weight loss through injections is rapidly growing in the U.S. and Europe, while nutra products still dominate in Asia and Latin America.
Why do Asia and Latin America prefer nutra products?
Affordability and Price: A course of injections costs $1,000+ per month, while nutra products are significantly cheaper.
Cultural Preferences: In Asia, the concept of «food as medicine» is deeply rooted, while in Latin America, people trust natural remedies.
Access to Prescription Medications: In many countries, prescription regulations limit the mass adoption of Wegovy and Mounjaro.
The future of the nutra market: adaptation or decline?
While injections are gaining popularity, the nutra industry isn’t backing down. Here’s what’s happening:
✔ Repositioning: Nutra products are now marketed as complements to injections, supporting metabolism and minimizing side effects.
✔ Growth in Nutra Sales for Blood Sugar and Appetite Control: Increasing demand for products based on berberine, magnesium, chromium, and adaptogens.
✔ Focus on Natural Ingredients: 75% of surveyed consumers (Euromonitor, 2024) say they prefer “natural weight loss solutions.”
Conclusion: will GLP-1 completely replace nutra products?
Not entirely—but the market is already transforming.
Injectable drugs dominate in the U.S. and Europe, while nutra products maintain their leadership in Asia and Latin America.
Nutra brands are adapting, offering supplements that support weight loss alongside injections.
What’s the winning strategy?
Most likely, a hybrid approach: injections + nutra support. This opens new opportunities for affiliate marketing!
Which trend do you prefer—GLP-1 injections or natural weight loss methods? Share your thoughts in the comments!
Share this article
Добавить комментарий